skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8121

Rituximab in severe skin diseases: target, disease, and dose

Other

(2324) Views  (873) Full article downloads

Authors: Daniel D Bennett, Maro Ohanian, Christian T Cable

Published Date July 2010 Volume 2010:2 Pages 135 - 141
DOI: http://dx.doi.org/10.2147/CPAA.S10929

Daniel D Bennett1, Maro Ohanian2, Christian T Cable2

1Department of Dermatology, 2Department of Internal Medicine, Division of Hematology and Oncology, Scott and White Healthcare, Texas A&M Health Science Center College of Medicine. Temple, TX, USA

Abstract: New clinical indications for rituximab seem to appear every day. This review will trace the use of this monoclonal antibody from lymphoid malignancy, to classic autoimmune disease, and specifically severe autoimmune skin diseases. The history leading to different dosing schema with associated pharmacokinetic data will be discussed. A case of livedoid vasculopathy (atrophie blanche) responding to rituximab will illustrate how the response to therapy can help to elucidate previously obscure pathophysiology.

Keywords: rituximab, livedoid vasculopathy, pharmacokinetics, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis




 

Other articles by Dr Christian Cable

The wandering spleen: an unusual case of thrombocytopenia
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University